iBio Reports Q1 Loss, Shares Down 49.4% YTD

iBio, Inc. reported a Q1 loss of $0.11 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07. Revenues for the quarter ended September 2025 were $0.1 million, in line with the Zacks Consensus Estimate. The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. The company has underperformed the market so far this year, with shares down 49.4% versus the S&P 500's gain of 16.4%. The Zacks Rank for the stock is #3 (Hold).